Tag Archives: CTXR stock research

Citius Pharmaceuticals (CTXR) posted a 24Q4 loss of $11.8 million or $1.64 per share.  Excluding an estimated $6 million milestone payment, which I had incorrectly expensed rather than capitalized, I had projected a $12.5 million or $1.73 per share loss.  … Continue reading →